Liver cancer drug shows promise in Late-Stage patients
NCT ID NCT05117957
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the drug sorafenib in 50 adults with advanced liver cancer that had worsened after at least one prior treatment. Participants took sorafenib daily to see if it could slow tumor growth and improve survival. The trial measured how long patients lived without their cancer getting worse and monitored side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sorafenib (a targeted cancer drug taken as a pill)
What this could lead to
If successful, this could provide a treatment option for patients with advanced liver cancer who have not responded to other therapies.
What could go wrong
This is a small, early-phase trial (50 participants) with no control group, so results may not be definitive. Sorafenib can cause side effects like fatigue, diarrhea, and skin reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cancer Center, Korea
Seoul, South Korea